VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$2.67 USD
+0.02 (0.75%)
Updated May 10, 2024 03:59 PM ET
After-Market: $2.66 -0.01 (-0.37%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
VYNE 2.67 +0.02(0.75%)
Will VYNE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VYNE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VYNE
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
VYNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now
What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Other News for VYNE
VYNE Stock Earnings: VYNE Therapeutics Beats EPS, Misses Revenue for Q1 2024
Buy Rating for VYNE Therapeutics on Strong Financial Footing and Promising Clinical Pipeline
VYNE Therapeutics GAAP EPS of -$0.15 beats by $0.09, revenue of $0.01M misses by $0.09M
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
VYNE Therapeutics reports Q1 EPS (15c) vs. ($1.74) last year